Investor Presentation

ANEB CEO Interview: Anebulo Pharmaceuticals’ development of a cannabis and THC antidote is revolutionizing the future health and safety for us all

Latest Financial Results

Latest Annual Filing

For Fiscal Year Ending Jun 30, 2021

Fact Sheet

Download

Cannabis associated ED visits are frequent and rapidly growing

Number of annual cannabis associated emergency department visits in the United States, 2006-2018

Note: Between 21% and 23% of all emergency department visits were captured by the National Emergency Department Sample (NEDS) in the years 2006-2014. The number of visits outside of the NEDS sample was extrapolated. Source for 2006-2014: Shen, J. J., Shan, G., Kim, P. C., Yoo, J. W., Dodge-Francis, C., & Lee, Y.-J. (2018). Trends and Related Factors of Cannabis-Associated Emergency Department Visits in the United States. Journal of Addiction Medicine, 1. doi:10.1097/adm.0000000000000479, Source for 2015-2018: Company analysis of NEDS database

Marijuana legalization is increasing

IR Contacts

Company

Anebulo Pharmaceuticals, Inc.
1415 Ranch Road 620 South
Austin, TX 78734
T: 512-598-0931
ir@anebulo.com

Investor Relations

LHA Investor Relations
Yvonne Briggs
T: 310-691-7100
ybriggs@lhai.com

Transfer Agent

Continental Stock Transfer & Trust Company
17 Battery Place
8th Floor
New York, NY 10004

Market Data copyright © 2021 QuoteMedia. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges). RT=Real-Time, EOD=End of Day, PD=Previous Day. Market Data powered by QuoteMedia. Terms of Use.